Transcenta has revealed results showing that Osemitamab (TST001) plus Nivolumab and CAPOX improved progression-free survival (PFS) in patients with HER2-negative metastatic gastric or gastroesophageal (G/GEJ) adenocarcinoma in a Phase I/IIa trial.
The TranStar102 study (NCT04495296) investigated osemitamab in combination with Opdivo (nivolumab) and CAPOX in 82 patients in cohort G.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Patients benefitted from a median PFS of 12.6 months in the patients with high or medium CLDN18.2 expression (H/M), 8.5 months in patients with low expression (L) and 6.7 months in the rest patients (R).
The confirmed response rate was 68%, 61.1% and 50% respectively.
The safety profile of the triple combination therapy is generally consistent with the previously evaluated osemitamab and CAPOX combination. The main toxicities are on-target-off-tumour effects, including nausea, hypoalbuminemia, and vomiting, mostly grade 1 or 2.
Transcenta will present the results on June 1 at the American Society of Clinical Oncology (ASCO) 2024 annual meeting in Chicago, US.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataTranscenta chief medical officer Dr Caroline Germa said: “In this population, the triple combo treatment delivered significantly better PFS benefits than that of the doublet combinations of checkpoint inhibitor/chemo or CLDN18.2 targeted antibody plus chemo.”
Germa added that the data further validates a global Phase III trial (NCT06093425) of the combination, which received US Food and Drug Administration (FDA) clearance in October 2023.
Osemitamab is a high-affinity humanised anti-CLDN18.2 monoclonal antibody that has shown potent anti-tumour activity. It acts by killing CLDN18.2 expressing tumour cells through antibody-dependent cellular cytotoxicity (ADCC).
G/GEJ cancer landscape
The G/GEJ cancer market across the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and South Korea) was valued at $1.12bn in 2019, a GlobalData report states, with the marker forecast to reach $4.72bn by 2029.
Growth is set to be driven by sales of Opdivo and Keytruda in the first-line metastatic setting, with immunotherapies expected to dominate the G/GEJ market.
GlobalData is the parent company of the Clinical Trials Arena.
